JAX Receives Funding for Genomics
News Oct 22, 2014
Technology investor David Roux and his wife Barbara have gifted $10 million to The Jackson Laboratory (JAX) to support research and find cures for genetically based diseases. The center will be based at the Laboratory’s locations in both Maine and Connecticut.
The newly announced Roux gift will be used to initiate the creation of the Roux Family Center for Genomics and Computational Biology. This center will be endowed with three new faculty chair positions and a permanent fund for recruiting expert staff and driving research and discovery at the Laboratory. The center will enable scientists to harness the full power of innovative genomic technologies and computational strategies, using them to analyze the human genome and discover new and better ways of preventing and treating disease. The Rouxs’ initial donation of $5 million will trigger a matching gift in their honor by JAX for a total gift of $10 million.
“At a time when public funding for disease research continues to dwindle, David and Barbara Roux have stepped forward to make a truly inspirational statement about the importance of supporting the future of genomic medicine in the shared quest to improve human health,” said Edison T. Liu, M.D., president and CEO of The Jackson Laboratory. “Their gift provides incredibly important leadership in this cause, and we are enormously grateful for their generosity.”
“Barbara and I are tremendously excited by the work that The Jackson Laboratory is doing in the area of genomic medicine,” said David Roux, co-founder and senior director of Silver Lake, one of the world’s leading private equity firms, and a member of the JAX board of trustees. “This remarkable research is transforming the world’s understanding of disease and the search for personalized and precise cures. We are privileged to help support these efforts.”
The Jackson Laboratory is an independent, nonprofit biomedical research institution based in Bar Harbor, Maine, with a facility in Sacramento, Calif., and a new genomic medicine institute in Farmington, Conn. It employs 1,600 staff, and its mission is to discover precise genomic solutions for disease and empower the global biomedical community in the shared quest to improve human health.
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
SCRaMbLE Speeds Up Yeast EvolutionNews
Scientists have created a new way of speeding up the genome evolution of baker’s yeast Saccharomyces cerevisiae. This is to develop a synthetic yeast strain that can be transformed on demand, making it industrial applications such as the mass production of advanced medicines to treat illnesses such as malaria and tuberculosis (TB).READ MORE
Artificial Cellular Compartments BuiltNews
How to install new capabilities in cells without interfering with their metabolic processes? A team from the Technical University of Munich (TUM) and the Helmholtz Zentrum München have altered mammalian cells in such a way that they formed artificial compartments in which sequestered reactions could take place, allowing the detection of cells deep in the tissue and also their manipulation with magnetic fields.READ MORE